HyperHep B (Hepatitis B Immune Globulin (Human)) - updated on RxList
A new study finds that daily low-dose aspirin may decrease the risk for hepatocellular carcinoma in patients with chronic hepatitis B infection.Medscape Medical News
(MedPage Today) -- Daily dose tied to 29% lower risk of developing common hepatitis B complications
We report 3 cases of association between ankylosing spondylitis and hepatitis B with the use of immunosuppressant drugs. Case 1 was a patient with previous HBV infection using DMARD. Cases 2 and 3 were patients chronically infected by HBV during immunosuppressant therapy. The management of HBV infection during immunosuppressant therapy is challenging and needs multidisciplinary support.
This nationwide cohort study examines the risk of hepatocellular carcinoma in Taiwanese patients with chronic hepatitis B who are receiving daily aspirin therapy.
Liver cancer (hepatocellular carcinoma [HCC]) incidence and mortality rates have been increasing in most countries for several decades. Currently, HCC is the second most common cause of cancer-related death in the world and represents the fastest rising cause of cancer-related deaths in the United States. Chronic hepatitis B virus (HBV) and hepatitis C virus are the primary underlying causes of HCC, with contributions from alcohol, tobacco, aflatoxin, obesity, and metabolic syndrome. In patients with chronic hepatitis C virus, the risk of HCC can be reduced rapidly with short-term, direct-acting antiviral medications. In c...
OMICS: A Journal of Integrative Biology,Volume 23, Issue 3, Page 167-179, March 2019.
The Journal of Alternative and Complementary Medicine, Ahead of Print.
(University of Melbourne) Australian researchers have used hepatitis B virus genome sequences to deduce that the mainland Aboriginal population separated from other early humans at least 59,000 years ago.
Authors: Ben Ayed H, Koubaa M, Yaich S, Rekik K, Ben Jemaa T, Maaloul I, Marrekchi C, Damak J, Ben Jemaa M Abstract OBJECTIVES: Several non-invasive markers have recently been proposed to predict liver fibrosis without percutaneous liver biopsy (PLB). We aimed to evaluate the performance of non-invasive scores and to highlight the value of a new combined score in the prediction of liver fibrosis in chronic hepatitis B (CHB) patients. PATIENTS AND METHODS: We performed a retrospective study of patients presenting with CHB who underwent PLB between 2008 and 2016. We calculated ASAT/Platelet Ratio Index (APRI), Fi...
ConclusionsDespite the limited number of studies retrieved, mostly old and focussed on populations with multiple risk factors, our findings highlight the importance of considering population groups at higher risk for HBV/HCV iatrogenic transmission as target groups for active case finding in the EU/EEA. Test offer should be guided by individual risk assessment alongside local epidemiological data and local context.